InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.91
(
0.54%
)
Bitcoin
60,248.33
(
-2.87%
)
Post# of 252476
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 85470

Thursday, 12/02/2010 5:34:49 PM

Thursday, December 02, 2010 5:34:49 PM

Post# of 252476
ODAC votes 10-0 that AZN’s vandetanib (a/k/a Zactima/ZD6474) for thyroid cancer should have a post-marketing study to find the best dose:

http://www.reuters.com/article/idUSN0222054620101202?feedType=RSS&feedName=governmentFilingsNews&rpc=43

Although the panel did not explicitly vote on whether the FDA should approve vandetanib for marketing, I interpret the vote on a post-marketing study to be an implicit vote for approval.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up